Status:
COMPLETED
MRI FDG PET Imaging Cervix
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Princess Margaret Hospital, Canada
Conditions:
Cervical Cancer Squamous Cell
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The standard treatment for cervix cancer at Princess Margaret Hospital is external radiation with chemotherapy followed by internal radiation, called brachytherapy. Currently, brachytherapy treatment ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Histologic diagnosis of squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix
- FIGO Stage IB - IVA
- Intention to treat using radiotherapy with or without concurrent cisplatin chemotherapy according to the current treatment policies of the PMH Gynecology Group
- Intention to treat with MR-guided brachytherapy as part of standard radiotherapy according to the current treatment policies of the PMH Gynecology Group
- No cytotoxic anti-cancer therapy for cervix cancer prior to study entry
- A negative urine or serum pregnancy test within the two week interval immediately prior to the first PET-CT imaging, in women of child-bearing age
- Ability to provide written informed consent to participate in the study
Exclusion
- Prior complete or partial hysterectomy
- Carcinoma of the cervical stump
- Inability to lie supine for more than 30 minutes
- Insulin-dependent diabetes mellitus
- Impaired kidney function with glomerular filtration rate \< 30
- Previous anaphylactic reaction to gadolinium or other contraindications to MR.
Key Trial Info
Start Date :
October 3 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT01899404
Start Date
October 3 2012
End Date
December 1 2016
Last Update
November 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network, The Princess Margaret
Toronto, Ontario, Canada, M5G 2M9